Results 161 to 170 of about 756,852 (217)

Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study. [PDF]

Orphanet J Rare Dis
Chan A, Kaempf M, Löscher WN, Vissing J, Voerman J, Frostell-Pyhäjärvi E, Atula S.   +6 more
europepmc   +1 more source

Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation. [PDF]

CNS Neurosci Ther
Zhou Q, He T, Cheng Y, Chen K, Ouyang Y, Dong X, Shi G, Wen Z, Yang H.   +8 more
europepmc   +1 more source

An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis. [PDF]

Drug Des Devel Ther
Xin H, Zhong Y, Zhang M, Wu L, Li Q, Li X, Wu Y, Zhang L, Peng J, Xie C, Zhu D, Hao Y, Guan Y, Wang K.   +13 more
europepmc   +1 more source

Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study. [PDF]

J Neurol
Oeztuerk M, Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, Lehnerer S, Stein M, Schubert C, Schneider-Gold C, Pfeuffer S, Krämer HH, Konen FF, Skripuletz T, Pawlitzki M, Rehmann R, Arat E, Menskes CB, Glaubitz S, Zschüntzsch J, Scherwietes V, Totzeck A, Hagenacker T, Meisel A, Meuth SG, Ruck T.   +26 more
europepmc   +1 more source

Double-Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity-Stratified Benefits in a Prospective Observational Multicenter Study. [PDF]

CNS Neurosci Ther
Wang K, Xin H, Zhang M, Li Q, Wu Y, Li X, Peng J, Xie C, Zhou X, Gao L, Pei X, Yang Y, Wang Y, Zhong Y, Zhang L, Zhu D, Guan Y.   +16 more
europepmc   +1 more source

Appropriate use of steroids for patients with generalized Myasthenia Gravis: an international Delphi study. [PDF]

Ther Adv Neurol Disord
Wiendl H, Murai H, Narayanaswami P, Saccà F, Silvestri NJ, Howard JF.   +5 more
europepmc   +1 more source

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). [PDF]

J Neurol
Howard JF, Saccà F, Hoffmann S, Attarian S, De Bleecker JL, Beauchamp J, Brauer E, Kerstens R, Vissing J, Meisel A, ADAPT Study Group.   +10 more
europepmc   +1 more source

Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety. [PDF]

J Clin Med
Di Martino G, Rini N, Bonaventura A, Trovato M, Maccora S, Lima SM, La Seta C, Brighina F, Di Stefano V.   +8 more
europepmc   +1 more source

Alterations in plasma cytokine profiles in generalized myasthenia gravis following different immunotherapeutic regimens. [PDF]

Front Neurol
Ren Z, Ma X, Liu Y, Zhang Y, Chen Y, Sun C, Qiu F.   +6 more
europepmc   +1 more source